IGF2BP3 can stabilize EGFR mRNA through m6A modification when KRAS is wild type, thereby continuously activating the downstream signaling pathway of EGFR, promoting tumorigenesis and evolution of CRC, and then affecting the sensitivity of patients with CRC to anti-EGFR monoclonal drug therapy. Here, KRAS is linked to colorectal carcinoma.